- A neutralizing antibody (Ab) shows promise against mild to moderate COVID-19 in a phase 2 trial.
- An interim analysis suggests that a single, intravenous (IV) infusion of the neutralizing Ab LY-CoV555 2800 mg (but not 700 or 7000 mg) accelerates decreased viral load at day 11, reduces hospitalization, and lowers symptom burden.
Why this matters
- Ongoing data collection will yield further information about LY-CoV555 IV efficacy for emergency, outpatient treatment of mild-moderate COVID-19.
- 452 patients (309 LY-CoV555, 143 placebo).
- Day 11, observed mean decline in log viral load from baseline:
- 2800 mg: −0.53 (P=.02, lower viral load factor=3.4).
- 700 mg: −0.20 (P=.38).
- 7000 mg: 0.09 (P=.70).
- Symptom score days 2-6 from baseline were slightly lower with LY-CoV555 vs placebo.
- Day 29 hospitalizations, pooled: 1.6% with LY-CoV555 vs 6.3% with placebo.
- Serious adverse events (AEs): 0.0% with LY-CoV555 vs 0.7% placebo.
- AEs: 22.3% with LY-CoV555 vs 24.5% placebo.
- Interim, phase 2 analysis from ongoing, randomized, double-blind, placebo-controlled, single-dose trial evaluating LY-CoV555 safety, efficacy in outpatients with mild to moderate COVID-19.
- Funding: Eli Lilly.
- Interim analysis; more data are needed.
- Inability to assess lower respiratory tract secretions.